Chengdu Jiwei Kang Biotechnology

Chengdu Jiweikang Biotechnology, also known as G-Micro Biotech, is a biotechnology company specializing in the development of circular RNA (circRNA) therapeutics and vaccines. The company leverages its proprietary G-Micro platform to design highly stable RNA molecules that offer prolonged protein expression compared to traditional linear mRNA. Jiweikang is focused on addressing unmet needs in infectious diseases, oncology, and rare diseases through its integrated RNA engineering and lipid nanoparticle (LNP) delivery technologies. Headquartered in Chengdu, China, the firm is supported by prominent venture capital investors and aims to advance the next generation of programmable RNA medicines.